Compare Macy's Inc (M) vs TG Therapeutics Inc (TGTX) Price & Performance

Macy's (M) trades at $23.92, down 3.94% in the last session, with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics including a P/E of 10.13 and P/S of 0.3, while maintaining positive cash flow generation. Recent institutional buying and analyst coverage indicate growing confidence in the company's turnaround strategy.

The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 4% upside potential. Key risks include retail sector headwinds and competitive pressures, but strong institutional interest and improving fundamentals support the case for gradual recovery. The dividend payment scheduled for July provides additional shareholder return.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.